| Literature DB >> 35196307 |
Haider Ghazanfar1, Paola Valeria Espinosa1, Cosmina Zeana2, Sridhar Chilimuri1, Donald Rudikoff3.
Abstract
BACKGROUND Cocaine is a highly addictive drug and its use has increased in recent years. It is the second most popular illicit drug in the United States and is the second most trafficked illicit drug in the world. Intravenous (i.v.) drug use leads to severe injury to the veins, including erythema, thrombophlebitis, vasoconstriction, necrosis, development of venous ulceration, and vein occlusion. CASE REPORT A 35-year-old man presented to our Emergency Department with a 3-day history of excruciating and progressive penile and scrotal pain after having injected cocaine in the dorsal vein of the penis. A genital examination revealed ulcerations and swelling on the ventral proximal penis and scrotum junction, with foul-smelling serous discharge. There was no crepitus. He also had stellate purpura with necrosis of the dorsum of the penis and tender bilateral inguinal lymphadenopathy. Computed tomography of the pelvis, with contrast, showed subcutaneous edema of the penis with ulceration of the penile tip on the right. It also revealed left inguinal adenopathy. Vasculitis and concomitant sexually transmitted disease were ruled out as well as Fournier gangrene, and he was started on i.v. broad-spectrum antibiotics. The patient's clinical condition improved with antibiotics and local wound care. CONCLUSIONS Our case highlights the importance of taking a thorough history from i.v. drug users, as they are at risk of injecting drugs into unusual sites, such as the dorsal penile vein. It is important for the physician to counsel active i.v. drug users regarding possible complications of injecting drug into unusual sites.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35196307 PMCID: PMC8884152 DOI: 10.12659/AJCR.935250
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Vasculitis and sexually transmitted disease workup.
|
|
|
|---|---|
| Human Immunodeficiency Virus (HIV) antibody | Negative |
| Urine Neisseria gonorrhoeae ribonucleic acid, transcription- mediated amplification (RNA, TMA) | Negative |
| Urine Chlamydia trachomatis RNA, TMA | Negative |
| Rapid plasma reagin (RPR) | Negative |
| Fluorescent treponemal antibody (FTA) | Negative |
| Hepatitis B core total antibody | Negative |
| Hepatitis B surface antibody | Positive |
| Hepatitis B surface antigen | Negative |
| Hepatitis C antibody | Positive |
| Hepatitis C viral load | Target not detected |
| Perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) | Negative |
| Cytoplasmic antineutrophil cytoplasmic antibody (C-ANCA) | Negative |
| Cardiolipin antibody Immunoglobulin (Ig) G | <14 (≤14 ZZ) |
| Cardiolipin antibody IgA | <11 (≤11 ZZ) |
| Cardiolipin antibody IgM | <12 (≤12 ZZ) |
| B2-Glycoprotein I Ig A | 35 (≤20 ZZ) |
| B2-Glycoprotein I Ig M | 14 (≤20 ZZ) |
| B2-Glycoprotein I Ig G | 12 (≤20 ZZ) |
| Antiphosphatidylserine IGG antibody | <10 (<10 U/mL) |
| Antiphosphatidylserine IGM antibody | <25 (<25 U/mL) |
| Antiphosphatidylserine IGA antibody | <20 (<20 U/mL) |
| Urine drug screen | Positive for cannabis, cocaine, methadone |